Intriguingly, CD6 is a risk susceptibility gene in IBD (61), and a higher proportion of CD4+ T cells derived from intestinal tissues from patients with IBD expressed CD6 compared with healthy subsets (62), indicating that CD6 could represent a potential therapeutic target in IBD. Here, CD4 is linked to inflammatory bowel disease.